arrow
W

William Rosenberg

university college london
H指数:65
被引数:3.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Results from a retrospective case finding and re-engagement exercise for people previously diagnosed with hepatitis C virus to increase uptake of directly acting antiviral treatment

从回顾性病例发现和重新参与运动的结果,以前被诊断为丙型肝炎病毒,以增加直接作用的抗病毒治疗的摄取

2024-09-060
OAAI
Progress is impossible without change: understanding the evolving nomenclature of steatotic liver disease and its effect on hepatology practice

没有变化就不可能取得进展: 了解脂肪肝疾病的演变命名法及其对肝脏病学实践的影响

2024-06-013
OAAI
Top ten research priorities for alcohol use disorder and alcohol-related liver disease: results of a multistakeholder research priority setting partnership

酒精使用障碍和酒精相关肝病的十大研究优先事项: 多利益相关方研究优先事项设定伙伴关系的结果

2024-05-013
PRE
Adjusted estimate of the prevalence of hepatitis delta virus in 25 countries and territories

25个国家和地区丁型肝炎病毒流行率的调整估计

2024-02-0125
OAAI
Hepatitis D double reflex testing of all hepatitis B carriers in low-HBV- and high-HBV/HDV-prevalence countries

在低HBV和高HBV/HDV流行国家中所有乙型肝炎携带者的丁型肝炎双反射检测

2023-08-0127
OAAI
Longitudinal Assessment of the Enhanced Liver Fibrosis Score in the Era of Contemporary HIV and Hepatitis C Virus Treatment

当代HIV和丙型肝炎病毒治疗时代增强肝纤维化评分的纵向评估

2022-07-275
OA
An entropic safety catch controls hepatitis C virus entry and antibody resistance

熵安全捕获控制丙型肝炎病毒进入和抗体抗性

2022-07-077
OA
Therapeutic Potential of TLR8 Agonist GS-9688 (Selgantolimod) in Chronic Hepatitis B: Remodeling of Antiviral and Regulatory Mediators

TLR8激动剂GS-9688 (Selgantolimod) 在慢性乙型肝炎中的治疗潜力: 抗病毒和调节介质的重塑

2021-06-2073
OAAI